$180M to Fix the Pill That Makes You Sick

Then in early 2026, vTv expanded that deal to give Newsoara exclusive worldwide rights. vTv got a $20 million upfront payment, plus up to roughly $115 million in milestone and royalty payments. Think of it as vTv deciding to become the landlord rather than the tenant: they no longer run development, but they still collect rent.

cAMPfield then swooped in and secured rights from Newsoara for everything outside China. A startup called Mountainfield Venture Partners conceived and created cAMPfield specifically to develop this drug for IBD. It's what the industry calls an "asset-centric NewCo": build the entire company around one promising molecule.

The Investor List Reads Like a Greatest Hits Album

Frazier Life Sciences led the round, with a supporting cast that includes Deep Track Capital, Forbion, Abingworth, Venrock, Longitude Capital, Novo Holdings, and RA Capital. If you follow biotech venture capital, you'll recognize almost every name on that list. These aren't tourists; they're the firms that consistently back drugs that make it to the finish line.

The $180 million makes this one of the largest Series A rounds in biotech this year, right alongside Alveus Therapeutics ($197M) and AirNexis Therapeutics ($200M). That kind of money for a single round signals something important: these investors aren't just interested; they're convicted.

The money will fund global Phase II/IIb trials in both moderate-to-severe ulcerative colitis and moderate-to-severe Crohn's disease. That's mid-stage testing, meaning the drug has already cleared early safety hurdles. The Series A is designed to generate the kind of data that either proves the concept or kills it.

Why IBD Is the Hottest (and Most Frustrating) Market in GI

The IBD drug market is enormous, projected to reach somewhere in the range of $25 to $35 billion by 2026. And yet, patient satisfaction is remarkably low.

The current oral options have real problems. JAK inhibitors like upadacitinib are effective, especially in tough-to-treat patients, but they carry FDA boxed warnings about serious infections, blood clots, and cardiovascular events. Doctors often won't prescribe them until patients have already failed other treatments. S1P receptor modulators like ozanimod are safer, but they require a baseline ECG before starting treatment and don't pack the same punch.

Both classes work, but neither class has nailed the combination that patients and doctors actually want: strong efficacy, clean safety, oral convenience, once-daily dosing. That's the white space cAMPfield is targeting.

The Competition Is Getting Crowded (and Creative)

cAMPfield isn't the only company chasing this opportunity. The oral IBD pipeline in 2026 looks like a packed restaurant on a Friday night.

There's icotyde, an oral peptide that targets the IL-23 receptor, trying to capture the stellar safety record of injectable IL-23 antibodies in a pill. There's obefazimod, a novel drug that works through microRNA-124, with recent data showing comparable efficacy and no new safety signals even in elderly patients (a group where JAK inhibitors are often avoided). And there's mufemilast, another PDE4 inhibitor showing encouraging remission data through 24 weeks.

The battlefield has shifted. It's no longer oral versus injectable. It's oral versus oral, with safety and tolerability as the deciding factors. Every new entrant needs to answer the same question: can you match the efficacy of biologics without the side-effect baggage?

So What's the Play?

cAMPfield's thesis is straightforward. If prifemilast's PDE4B selectivity translates into a genuinely cleaner side-effect profile in mid-stage trials, it could carve out a meaningful niche. The IBD market is one where patients cycle through multiple therapies over a lifetime, and doctors are desperate for options they can prescribe without agonizing over safety trade-offs.

But "selective" and "better tolerated" are promises that need proof. The Phase II data will either validate the sniper-rifle theory or show that PDE4B selectivity doesn't matter as much as the preclinical work suggests. At $180 million, the investors clearly believe the odds are favorable.

The broader signal is just as interesting as the specific drug. In a biotech funding environment that's been cautious (some would say stingy), a nearly $200 million debut round for an oral IBD drug tells you where smart money thinks the next wave of value creation is heading. Not gene therapy. Not AI-designed proteins. A good old-fashioned pill that works better and hurts less.

Sometimes the most radical innovation is simply fewer side effects.

The Lung Cancer Drug Where Half the Patients Are Still Winning After 7 Years

Seven years into a clinical trial, more than half of metastatic lung cancer patients on Pfizer's lorlatinib still haven't progressed. Oncologists are starting to whisper the word "cure," and the data might actually justify it.